Calamos Advisors LLC Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Calamos Advisors LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 143,623 shares of the medical research company's stock after selling 23,327 shares during the quarter. Calamos Advisors LLC's holdings in Thermo Fisher Scientific were worth $76,234,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 0.6% in the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company's stock valued at $16,582,503,000 after buying an additional 180,618 shares in the last quarter. Morgan Stanley lifted its stake in Thermo Fisher Scientific by 0.4% in the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company's stock valued at $6,285,838,000 after buying an additional 50,736 shares in the last quarter. Moneta Group Investment Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 104,536.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company's stock valued at $4,601,150,000 after purchasing an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 61,754.7% in the first quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company's stock valued at $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $3,105,677,000. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a report on Thursday, April 4th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 target price on the stock. Finally, Royal Bank of Canada boosted their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $604.69.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $5.47 on Thursday, hitting $541.78. The company had a trading volume of 2,075,782 shares, compared to its average volume of 1,547,352. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock has a market cap of $206.80 billion, a price-to-earnings ratio of 35.07, a P/E/G ratio of 2.33 and a beta of 0.80. The stock has a 50 day moving average price of $571.39 and a 200 day moving average price of $527.11. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company's quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the company earned $5.40 earnings per share. Analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is presently 10.10%.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the business's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company's stock, valued at $7,250,362. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company's stock, valued at $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.